Easton Pharmaceuticals, Inc. To Purchase An Interest In Pending Medical Marijuana Operation

Publishing & Media

Share Tweet

Easton Pharmaceuticals, Inc. To Purchase An Interest In Pending Medical Marijuana Operation

Easton Pharmaceuticals, Inc. (OTCPINK: EAPH) saw its share volume soar on June 2nd with 38,145,068 shares exchanging hands, more than double its three month daily average volume of 15,055,419 shares.

This uptick in volume comes after Easton Pharmaceuticals announced today that it has signed an agreement to purchase an interest in a pending medical marijuana operation.

Easton Pharmaceuticals is pleased to announce that it has entered into an agreement with Canadian based MDRM Group (Canada) Ltd., a wholly owned subsidiary of Modern Mobility Aids, Inc., a Nevada corporation (OTCBB: MDRM). The agreement allows Easton to purchase up to 49% of a private Canadian medical marijuana company that has submitted an application for a federal growers license and has received a letter to build from Health Canada under Canada's new MMPR system.

This agreement represents the first and potentially the most lucrative medical marijuana agreement that Easton has closed on with other anticipated closing agreements and announcements in the medical marijuana industry. Easton Pharmaceuticals additionally announces it has signed an LOI agreement and has entered into negotiations with UMED Health and Wellness Centers who currently own an operating medical marijuana dispensary in the State of Michigan who maintain approximately 1500 patients. Easton's discussions involve an investment into UMED as well as the opening of new additional dispensaries in the State of Michigan where Easton would potentially maintain a majority ownership in.

EAPH closed the day at $.021.


Amarantus Bioscience Holdings, Inc. To Present At LD Micro Invitational

Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) saw its share volume rise on June 2nd with 10,720,811 shares exchanging hands, double its three month daily average volume of 5,040,671 shares.

Amarantus Bioscience Holdings, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald E. Commissiong, President and CEO will present at the LD Micro Invitational on Wednesday, June 4th, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles.

"We are honored to have Amarantus present at the conference," stated Chris Lahiji, President of LD Micro.

AMBS closed the day at $.1041, 13.77% higher than its previous close of $.0915.


OncoSec Announced Interim Data From Its Phase 2 Melanoma Study

OncoSec Medical Inc. (OTCQB: ONCS) saw its share volume soar on June 2nd with 4,046,742 shares exchanging hands, significantly higher than its three month daily average volume of 2,664,931 shares.

This uptick in volume comes after OncoSec Medical announced interim data from its Phase 2 melanoma study at the American Society of Clinical Oncology's (ASCO) 50th Annual Meeting in Chicago. The abstract, titled "Systemic anti-tumor effect and clinical response in a Phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma" (ASCO Abstract #9025), was presented by Adil Daud, M.D., OncoSec's Chief Clinical Strategist and Principal Investigator of the Phase 2 melanoma study, and selected for discussion during a poster highlights session for melanoma/skin cancers led by Axel Hauschild, M.D., Ph.D.

Data from the multicenter, open-label, single-arm study confirmed the safety of OncoSec's lead product candidate, ImmunoPulse, which delivers the anti-tumor agent pIL-12 directly into the tumor via in-vivo electroporation (EP), with no treatment-related serious adverse events or deaths having been reported. Regression of treated and non-treated tumors suggests successful induction of systemic anti-tumor response.

To date, 30 patients have been enrolled and have received at least one cycle of treatment. At the time of this interim analysis, 28 patients were evaluable for objective response rate (ORR) at 24-week primary time point.

OncoSec's Chief Medical Officer, Robert H. Pierce, M.D., commented: "Taken together, these data—the systemic clinical responses, the gene expression pattern in the treated lesions in patients and our analysis of treated and untreated tumors in B16 mouse model—form a coherent picture of IL-12's mechanism of action as a potent enhancer of tumor immunogenicity. In summary, intratumoral IL-12 appears to 'de-cloak' the tumor, allowing the immune system to see the tumor as 'foreign' and generate the CD8 T cells needed to mount an attack. These findings are incredibly important given the emerging understanding that a prerequisite for response to T cell checkpoint therapies such as anti-PD-1 mAbs is the presence of the PD-1+ CD8 T cells."

"To establish our leadership, we have been strongly investing in our R&D infrastructure and these efforts are paying off, and we expect OncoSec to be the most innovative and scientifically driven intratumoral immunotherapy company in the industry" said Punit Dhillon, President and CEO of OncoSec. "The more we understand IL-12's mechanism of action, the better positioned we are to expand our development into other targets as well as drive rational combinations in the clinic, and that's OncoSec's development path forward."

ONCS closed the day at $.84, 2.44% higher than its previous close of $.82.

PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:



Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.

Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.pennypickalerts.com


Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.